NCT05562362View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

November 12, 2020

Study Completion Date

November 12, 2020

Conditions
Healthy Subjects
Interventions
DRUG

RE-021, sparsentan

RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Trial Locations (1)

NG11 6JS

Travere Investigational Site, Nottingham

All Listed Sponsors
lead

Travere Therapeutics, Inc.

INDUSTRY

NCT05562362 - Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension | Biotech Hunter | Biotech Hunter